Second Sight Medical Products Inc (NASDAQ:EYES) recently announced that it has achieved a remarkable feat in the world of ophthalmology by carrying out a record number of Argus II Retinal Prosthesis Systems implants. The company has also successfully carried out first-in-human Orion Cortical implant. These new milestones have helped the company get a sound opening in the trading market.
The highlights of the achievements announced on January 31, 2018, include:
- Implantation of 30 Argus II Retinal Prosthesis Systems globally during the fourth quarter of last year for around 75 implants in 2017
- Carried out seven implants in the fourth quarter of 2017 and a total 42 implants in 2016 representing a growth of 329% and 79% in the value of implants respectively in both these years
- Nader Pouratian, MD, Ph.D., Vice Chairman of the Department of Neurosurgery at the Ronald Reagan UCLA Medical Center (UCLA) carried out the first human patient implant with the Orion Cortical Visual Prosthesis System (Orion) in late January as a part of the feasibility clinical study of Second Sight.
- The company is expecting enrollment of first patient(s) for the first quarter of 2018 in a clinical study of better-sighted patients suffering from Retinitis Pigmentosa (RP) in Germany.
- A report says that two sites are already screening the subjects for the study actively whereas the third site is to résumé screening shortly.
According to CEO & President of Second Sight, Will McGuire, they are excited about Company’s milestones and achievements for the last year which speak about Second Sight’s strength of the business and the milestone that the Company wants to continue to achieve in 2018.
Chairman of the Board, Dr. Robert Greenberg said that the first-in-human implant of the Orion is a significant milestone for the Company and a critical step forward in meeting Second Sight’s mission to develop devices that could potentially cure nearly all forms of blindness. Greenberg said that they are expecting that an additional four patients will be a part of this feasibility study at the Baylor College of Medicine and UCLA in Houston.